|
| What are this week’s market risks or opportunities? |
|
|
| This week the AI chip names climbed back almost as fast as they fell. A week earlier, $1.4 trillion had come off the sector in a single day, led by Nvidia. |
|
| Nothing about these companies changed. What changed was the interest-rate outlook. A strong jobs report made investors think the Fed has less room to cut, and when rates look higher for longer, stocks priced on far-in-the-future profits get hit hardest. |
|
| That includes much of the AI trade. |
|
| So in the near term, these swings come from rates and risk appetite, and they shift how quickly the AI trade plays out. |
|
| You can see it right now: US inflation at a multi-year high of 4.2% on an energy shock from the Iran conflict, and a wave of AI mega-IPOs led by SpaceX testing investor nerve. Both move the mood around the AI names you own, not their actual earnings. |
|
| For your portfolio, the question is whether a stock is broken or just out of favor. If it's sound, a rate-driven drop is mostly noise, sometimes a chance to add. |
|
|
|
|
|
|
| Which trades should I consider? |
|
|
| Since rates can stretch out how long the AI trade takes to pay off, the safer names are the ones that already make money and still look cheap for how fast they're growing. |
|
| Take Adobe, Salesforce, and Intuit. Their earnings are still growing fast, but their shares have fallen this year, so you are paying less for that growth than before. The cash they generate today funds the next stage without leaning on cheap borrowing. |
|
| Compare that to a name like Zscaler. The growth is real, but the price already assumes years of it, so the stock swings hardest every time the rate outlook moves. |
|
| In a market this sensitive to the Fed, leaning toward profitable growth you are not overpaying for keeps you in the AI theme while putting less of the position at the mercy of the next rate headline. |
|
|
|
|
|
|
| Should I consider this trade? |
|
|
| If you want a corner of the market with nothing to do with the AI trade, healthcare is quietly working again. It's a rebound led by individual names rather than the whole sector, so the names you pick matter. |
|
| One that stands out is Haemonetics, a medical technology company that makes the blood and plasma systems hospitals rely on. |
|
| It's up 44.3% since September as a pick in our ProPicks AI Healthcare Heroes strategy, backed by an earnings beat ($1.10 against $1.01 expected). |
|
| The catch is timing. |
|
| This WarrenAI analysis for HAE shows that after a sharp run, the stock is technically overbought and stretched above its recent average price, so buying here does carry pullback risk. |
|
|
|
|
|
|
| Data correct to 10.06.2026 |
|
